Pliant Therapeutics, Inc.
PLRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001746473
No open-market purchases or sales by Pliant Therapeutics, Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $54.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Pliant Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Pliant Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Iannone Robert | Director | – | Jul 13, 2026 | 1 |
| Borellini Flavia | Director | – | Jul 13, 2026 | 1 |
| Crowell Gayle A | Director | – | Jun 12, 2026 | 1 |
| Huh Hoyoung | Director | – | Jun 12, 2026 | 1 |
| MCCOURT Thomas A | Director | – | Jun 12, 2026 | 1 |
| Curnutte John T | Director | – | Jun 12, 2026 | 1 |
| Cline Darren S | Director | – | Jun 12, 2026 | 1 |
| Krognes Steve E. | Director | – | Jun 12, 2026 | 1 |
| Coulie Bernard | President and CEO | 505,601 | Apr 17, 2026 | 3 |
| Cummings Keith Lamont | Chief Financial Officer | 297,214 | Apr 17, 2026 | 3 |
| Cheung Lily | Chief Human Resource Officer | 44,847 | Apr 17, 2026 | 3 |
| Kuo Minnie | Chief Operating Officer | 37,806 | Apr 17, 2026 | 3 |
| Pyott David E I | Director | – | Jun 9, 2025 | 0 |
| Bruhn Suzanne Louise | Director | – | Jun 9, 2025 | 0 |
| Knobil Katharine | Director | – | Jun 9, 2025 | 0 |
| Lefebvre Eric | Chief Medical Officer | 240,224 | Jan 27, 2025 | 0 |
| Hull Hans | Chief Business Officer | 251,708 | Jan 27, 2025 | 0 |
| Ouimette Mike | General Counsel & Corp. Sec'y | 105,544 | Jan 27, 2025 | 0 |
| Shah Smital | Director | – | Jun 17, 2024 | 0 |
| Tepper Robert I | 10% Owner | 1,839,160 | Dec 1, 2022 | 0 |
| Third Rock Ventures III, L.P. | 10% Owner | 1,839,160 | Dec 1, 2022 | 0 |
| TRV GP III, LLC | 10% Owner | 1,839,160 | Dec 1, 2022 | 0 |
| Third Rock Ventures GP III, L.P. | 10% Owner | 1,839,160 | Dec 1, 2022 | 0 |
| Exter Neil | Director | – | Jun 21, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Kuo MinnieChief Operating Officer | SSale | −6.92K | $1.28 | −$8.85K | −15.5%37.8K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Coulie BernardPresident and CEO | SSale | −89.4K | $1.28 | −$114.4K | −15.0%505.6K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Cheung LilyChief Human Resource Officer | SSale | −7.53K | $1.28 | −$9.64K | −14.4%44.8K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Cummings Keith LamontChief Financial Officer | SSale | −24.0K | $1.28 | −$30.7K | −7.5%297.2K after | 10b5-1 |